Kiryat Ono, Israel

Jordan Chill

This inventor holds 1 USPTO granted patent. Top assignee: Bar-Ilan University. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jordan Chill. Retrieved from https://idiyas.com/inventor/jordan-chill

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Jordan Chill and a Peptide-Based Approach to Cancer Metastasis

Introduction

Jordan Chill is an inventor based in Kiryat Ono, Israel, whose work includes a patent concerning a potential approach to inhibiting cancer metastasis. He is associated with Bar-Ilan University. His patent describes a Pyk2-derived peptide designed to interfere with invadopodia-mediated cancer spread.

Latest Patents

Chill is named on 1 patent: “Pyk2-derived peptides for inhibiting invadopodia-mediated cancer metastasis.” The invention describes an isolated Pyk2-derived peptide containing a consensus proline-rich region 2 (PRR2) sequence, PxxPx(R/K)P(K/R)(Y/W/F), where “x” represents any amino acid. The peptide is designed to bind to a Src homology 3 (SH3) domain of cortactin and inhibit metastasis.

The patent also describes methods for treating cancer and preventing or inhibiting cancer invasion and metastasis by administering the peptide, optionally in combination with an anti-cancer agent.

Career Highlights

Chill’s listed patent connects his work with research into cancer invasion and metastasis. The invention focuses on a molecular strategy intended to disrupt processes associated with invadopodia, structures that cancer cells can use to invade surrounding tissue.

Collaborations

Chill’s listed coworker is Hava Gil-henn. The patent’s association with Bar-Ilan University reflects an academic research setting for the work.

Conclusion

Jordan Chill’s patent presents a peptide-based strategy for targeting cancer metastasis by binding cortactin’s SH3 domain, highlighting a research direction with potential relevance to cancer treatment.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…